Mastoiditis

Summary

Mastoiditis (MONDO:0000748) is a disease and 6 clinical trials. Top therapeutic interventions include sulfamethoxazole and trimethoprim. A subtype of bone inflammation disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mastoiditis
Mondo ID	MONDO:0000748
MeSH	D008417
DOID	DOID:0060322
NCIT	C128368
SNOMED CT	52404001
UMLS	C0024904
MedGen	7480
Is cancer (heuristic)	no

Also known as: inflammation of mastoid process of temporal bone · mastoid process of temporal bone inflammation · mastoid process of temporal boneitis · mastoiditis · mastoiditis (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of bone inflammation disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › bone disorder › bone inflammation disease › mastoiditis

Related subtypes (5): epicondylitis, Osgood-Schlatter disease, osteomyelitis, arthritic joint disease, Caffey disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dexamethasone	Phase 3 (in late-stage trials)
Sodium Chloride	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06982105	PHASE4	RECRUITING	Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
NCT00502450	Not specified	WITHDRAWN	Is There Hearing Loss After Acute Mastoiditis
NCT00714402	Not specified	COMPLETED	Procalcitonin Level and Kinetics in Children With Bacterial Infections
NCT01272999	Not specified	COMPLETED	Impact of Prevnar 13 on Ear Infections in Children
NCT03864055	Not specified	COMPLETED	Otogenic CSVT Retrospective Case Series and Associated Thrombophilia
NCT07122440	Not specified	COMPLETED	Outcomes and Prognostic Factors of Acute Mastoiditis in the Grand-Est Region

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SULFAMETHOXAZOLE	4	1
TRIMETHOPRIM	4	1